ANIK EBITDA Growth
Anika Therapeutics Inc · EBITDA Growth
ANIK EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported173.10%period ending
ANIK TTM EBITDA YoY % (-16.67% → 173.10%)
Year-over-year change
High-resolution chart · PNG
ANIK ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 173.0986% | |
| -1,337.5% | |
| -679.5207% | |
| 183.4593% | |
| -20.8509% | |
| 90.4707% | |
| 95.1669% | |
| -76.0296% | |
| 75.5149% | |
| 72.7496% | |
| -131.352% | |
| -138.8198% | |
| -373.6347% | |
| -212.1849% | |
| 1.3932% | |
| -175.2429% | |
| 31.2176% | |
| 10.7828% | |
| -314.6414% | |
| -127.3683% | |
| -117.7602% | |
| -112.2591% | |
| -102.4328% | |
| -82.8998% | |
| -49.0959% | |
| -11.4407% | |
| 48.6993% | |
| 69.0835% | |
| 48.7977% | |
| 20.2591% | |
| -44.5131% | |
| -48.3976% | |
| -48.7753% | |
| -32.8273% | |
| -7.9535% | |
| -9.8196% | |
| -2.1635% | |
| -6.4164% | |
| 8.6327% | |
| 29.837% | |
| 31.4393% | |
| 16.3236% | |
| -24.3827% | |
| -30.1579% | |
| -29.8532% | |
| -15.3026% | |
| 78.3453% | |
| 75.8425% | |
| 95.0719% | |
| 103.1189% | |
| 50.8046% | |
| 92.8796% | |
| 59.2532% | |
| 57.4828% | |
| 63.6862% | |
| 53.9466% | |
| 107.0397% | |
| 125.3228% | |
| 78.8371% | |
| 36.0463% | |
| 6.693% | |
| -11.4544% | |
| 0.3936% | |
| 53.9523% | |
| 72.9255% | |
| 91.8293% | |
| 82.8399% | |
| 9.9829% | |
| -14.4768% | |
| -32.408% | |
| -38.194% | |
| -9.7894% | |
| 7.3047% | |
| 11.6656% | |
| 27.4391% | |
| 2.417% | |
| -29.221% | |
| -26.175% | |
| -35.492% | |
| -45.1214% | |
| -2.5125% | |
| 7.5823% | |
| 29.9437% | |
| 94.7513% | |
| 99.2285% | |
| 171.4742% | |
| 413.9362% | |
| 376.4574% | |
| 6,812.7573% | |
| 377.5469% | |
| 157.4257% | |
| 132.8645% | |
| 101.55% | |
| 81.4899% | |
| 60.5365% | |
| -4.2267% | |
| -5.0774% | |
| -314.546% | |
| -2,876.7403% | |
| -70.7499% |